Document ID: chunk:federal_register_of_legislation:C2022C00026:clause:3_5
Version: federal_register_of_legislation:C2022C00026
Segment Type: clause
Provision Reference: sch 3 cl 5
Character Range: 42854–43567

5  After subsection 99ADH(2)
Insert:
 (2A) For the purposes of paragraph (1)(c), the drug and manner of administration of a pharmaceutical item is taken to have been on F2 for at least 42 months if:
 (a) at end of the previous data collection period, the drug in the WADP brand had been on F2 for at least 42 months; and
 (b) on a day at least 42 months before the end of the previous data collection period:
 (i) there was a related brand of the WADP brand that had the same pharmaceutical item as, or was bioequivalent or biosimilar to, the WADP brand; or
 (ii) there were 2 or more related brands of the WADP brand that had the same pharmaceutical item as, or were bioequivalent or biosimilar to, each other.